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Abstract
Aim
Diabetes is a serious global health problem. A simple and effective screening tool should
have substantial public health benefit. We investigated the performance of the latest Ameri-
can Diabetes Association diabetes screening methods in our aging Chinese population.
Methods
Subjects without diabetes who returned for the 4th Hong Kong Cardiovascular Risk Factors
Prevalence Study in 2010–2012 were evaluated for the probability of having diabetes with
reference to the age- and body mass index-based screening criteria (screening criteria) and
the diabetes risk test (risk test), and the conclusion drawn was compared to their measured
glycaemic status. Diabetes was defined by fasting glucose 7 mmol/L or 2-hour post oral
glucose tolerance test glucose 11.1 mmol/L.
Results
1415 subjects, aged 58.1±10.2, were evaluated. 95 (6.7%) had diabetes. The risk test
showed good accuracy (area under the receiver operating curve 0.725) in screening for dia-
betes with an optimal cut-off score of five. Compared to the screening criteria, the risk test
had significantly better specificity (0.57 vs. 0.41, p<0.001), positive predictive value (0.12
vs. 0.09, p<0.001) and positive diagnostic likelihood ratio (1.85 vs. 1.37, p<0.001). To diag-
nose one case of diabetes, fewer subjects (11 vs. 18) needed to be tested for blood glucose
if the risk test was adopted.
Conclusion
The risk test appears to be a more effective screening tool in our population. It is simple to
use and can be adopted as a public health strategy for identifying people with undiagnosed
diabetes for early intervention.
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Introduction
Diabetes is a serious global health problem, with the worldwide prevalence of diabetes having
more than doubled in the past two decades [1]. Many of these subjects with diabetes, 60.6% in
China [2] and 45.8% in the world [3], were undiagnosed, likely attributable to the prolonged
asymptomatic phase between the onset of hyperglycemia and diagnosis of type 2 diabetes.
Thus at the time of diagnosis, many patients with diabetes may have already developed chronic
diabetic complications. In the UK Prospective Diabetes Study, for instance, the prevalence of
retinopathy, proteinuria and impaired vibration perception was 36, 1.9 and 11.5% respectively
in newly diagnosed patients [4]. In Hong Kong, the prevalence of retinopathy in those with
newly diagnosed diabetes was reported to be 22% [5]. Early diagnosis, before the appearance
of irreversible tissue damage, offers the best chance for complication prevention. Delivering
diabetes screening to all adults in a populous country like China is difficult. However, opportu-
nistic diabetes screening by a practical and effective screening tool, might have substantial
public health benefit.
The list of diabetes risk factors is lengthy. It is important that the general public, healthcare
professionals and policy makers are informed of the relative strength and the way to make use
of the individual risk factors. Screening for diabetes through an assessment of risk factors with
regard to an age- and body mass index (BMI)-based criteria (screening criteria); or with the
American Diabetes Association (ADA) diabetes risk test (risk test) is recommended by the
ADA to guide healthcare providers on whether or not a diagnostic test, i.e. blood glucose or
HbA1c measurement, is necessary. The screening criteria suggested that adults aged 45 and
older should be tested for diabetes every three years and testing should start earlier than 45 in
overweight individuals with one or more of the risk factors for diabetes [6]. In Hong Kong, as
47.0% of our aging population were aged 45 or older in 2015 [7], a large proportion of our pop-
ulation would need regular diagnostic tests for diabetes if we adopt the screening criteria to
test all subjects aged 45 or over [6]. A similar problem is anticipated in China, in particular in
the urban areas, where population aging is evident, and regular blood glucose screening in all
individuals older than 45 years would impose a huge burden to the public healthcare system.
The ADA diabetes risk test, which was modified from the model developed using the data of
NHANES 1999–2004 by Bang et al in 2009 [8], has been recommended as an additional option
for screening [6]. We are interested to know which screening strategy better suits our aging
Chinese population.
Here we evaluated the screening criteria and risk test using data from 1415 Hong Kong Chi-
nese subjects who had no diabetes at prior assessments and returned for the 4th Hong Kong
Cardiovascular Risk Factors Prevalence Study (CRISPS) in 2010–2012. Our study provides
insight on the performance of the two well validated, easily accessible and commonly used
ADA diabetes screening recommendations, which involve non-invasive and easily measurable
parameters, for diabetes screening in the Chinese population.
Methods
Participants
CRISPS. Subjects were recruited from the CRISPS, a long-term, population-based, pro-
spective study on the development of cardiovascular risk factors in Hong Kong. In 1995–1996
(CRISPS1), 2,895 unrelated Chinese subjects were invited randomly by their telephone num-
bers to undergo a detailed assessment [9]. Subjects were contacted for reassessment visits in
2000–2004 (CRISPS2), 2005–2008 (CRISPS3) and 2010–2012 (CRISPS4). Details of medical
history taking, anthropometric and biochemical parameters measurements were described
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elsewhere [10, 11]. The presence of hypertension was defined as blood pressure 140/90
mmHg or receiving regular antihypertensive treatment [12]. A 75g OGTT was done in all sub-
jects not taking antidiabetic medications when they attended assessment from CRISPS1 to
CRISPS4. Diabetes cases were defined as being on medications for diabetes or having diabetes
according to the World Health Organization (WHO) 1998 criteria: fasting glucose (FG) 7
mmol/L or 2hours post OGTT glucose (2-hG) 11.1 mmol/L.
All subjects with no diabetes at prior assessments (550 or 38.9% were known to have
impaired glucose tolerance and/or impaired fasting glucose) who returned for follow-up at
CRISPS4 were evaluated for the probability of having diabetes with reference to the ADA
screening criteria and risk test, and the conclusion drawn was compared to their measured gly-
caemic status at the CRISPS4 assessment (S1 File). The ADA diabetes risk test is the risk score
based on seven parameters including age, gender, family history of diabetes, history of gesta-
tional diabetes in women, history of hypertension, physical activity and body mass index of the
individual. Subjects with a score of five or above are considered to have high risk of having dia-
betes [6]. The study protocol was approved by the Ethics Committee of the Faculty of Medi-
cine, University of Hong Kong. Written informed consent was obtained from all subjects.
Statistical analysis. All analyses were performed with SPSS version 23 software (SPSS,
Inc., Chicago, IL). Results were presented as mean ± SD or median with interquartile range
(IQR) as appropriate. For data that were not normally distributed, natural logarithmic trans-
formation was applied before analyses. In univariate analyses, variables were compared
between groups by one-way ANOVA for continuous data and Chi-square test for categorical
data as appropriate. The area under the receiver operating characteristic (ROC) curve
(AUROC) of the risk score was calculated to assess the performance in identification of diabe-
tes subjects. The optimal cut-off for the risk score was determined by Youden’s index [13] and
compared to the ADA recommended cut-off value. The sensitivity, specificity, positive (PPV)
and negative predictive values (NPV), diagnostic positive and negative likelihood ratios
(DLRs) of the screening criteria and risk test were calculated for comparison. The number
needed to test for blood glucose levels to diagnose one case of diabetes (NNT) was calculated
by a reciprocal of absolute risk reduction [14]. Comparison of binary diagnostic tests in a
paired study design were performed using R (package DTComPair) [15]. Differences in sensi-
tivities and specificities were compared using McNemar’s test [16]. Positive (PPV) and nega-
tive predictive value (NPV) were compared as proposed by Moskowitz and Pepe [17], and
diagnostic positive and negative DLRs were compared using a regression model approach
[18].
Results
At CRISPS4, 1415 subjects (age: 58.1±10.2) with no diabetes at the last preceding assessment
returned for follow up and 95 (6.7%) were diagnosed to have diabetes (S1 File). Table 1 shows
that at CRISPS4, compared to those without diabetes, subjects with newly diagnosed diabetes
were significantly older, more obese, had greater BMI and waist circumference (WC), and had
higher systolic and diastolic blood pressures. They were also more likely to have hypertension
(all p<0.001).
The AUROC of the risk test for identification of subject with diabetes was 0.725 with cut-
off score being optimal at five, which was identical to the suggested cut-off by ADA (Table 2).
The statistical measures of the performance of the two screening methods in evaluation for the
subjects at CRISPS4 are shown in Table 3. The risk test had significantly better specificity (0.57
vs. 0.41, p<0.001), positive predictive value (0.12 vs. 0.09, p<0.001) and positive diagnostic
likelihood ratio (1.85 vs. 1.37, p<0.001). There was no significant difference in sensitivity,
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negative predictive value and negative diagnostic likelihood ratios, when compared with the
screening criteria (Table 3). In addition, the risk test had smaller NNT (11 vs. 18), compared to
the screening criteria. 859 (60.7%) of the CRISPS4 subjects needed to have glucose measure-
ment using the screening criteria but the number would reduce to 647 (45.7%) if the risk test
was adopted as the screening tool.
Table 1. Baseline characteristics of 1415 subjects at CRISPS4.
Variables All DM Non-DM p-value
Number 1415 95 1320 - -
Age, years 58.1±10.2 62.5±10.4 57.8±10.1 <0.001
Gender, % men 45.7 46.3 45.6 0.893
Smoking (%) 0.152
Never smoke 72.7 69.5 72.9
Former smoker 17.2 14.7 17.4
Current smoker 10.1 15.8 9.7
Physical inactivity, % 49.2 50.5 49.1 0.787
FG, mmol/L 5.08±0.92 6.89±2.44 4.95±0.48 <0.001
2hG, mmol/L 6.63±2.86 14.2±3.89 6.09±1.80 <0.001
A1C, % 5.89±0.63 7.04±1.52 5.80±0.40 <0.001
A1C, mmol/mol 40.9±6.93 53.4±16.6 39.9±4.42 <0.001
First degree of relative with DM, % 28.7 41.1 27.8 0.006
History of GDM, % 1.1 2.1 1.0 0.303
BMI, kg/m2 24.1±3.47 26.4±4.10 24.0±3.36 <0.001
Waist circumference, cm 82.1±9.61 88.7±9.94 81.6±9.41 <0.001
Central obesity, % 36.1 63.2 34.2 <0.001
Waist-to-hip ratio 0.87±0.07 0.92±0.06 0.87±0.07 <0.001
SBP, mmHg 125±18.5 134±18.7 124±18.3 <0.001
DBP, mmHg 74.1±10.3 77.6±12.4 73.9±10.1 0.001
HT, % 39.1 67.4 37.1 <0.001
Triglycerides *, mmol/L 1.10 (0.80–1.50) 1.50 (1.10–2.00) 1.10 (0.80–1.50) <0.001
HDL- Cholesterol, mmol/L 1.49±0.41 1.31±0.34 1.51±0.41 <0.001
LDL- Cholesterol, mmol/L 3.12±0.82 3.28±0.89 3.11±0.81 0.055
Data presented as mean±SD or median (interquartile range);
*log-transformed before analysis. Central obesity: WC90 for men and 80 for women; HT, hypertension: BP 140 / 90mmHg or taking antihypertensives.
https://doi.org/10.1371/journal.pone.0184840.t001
Table 2. Different cut-off points for the ADA diabetes risk test when applied in the CRISPS population (n = 1415).
AUROC (95% CI) Risk score Cut-off Sensitivity, % Specificity, % PPV, % NPV, %
0.725 (0.673–0.776) 1 100.00 0.00 6.7 0.0
2 100.00 2.0 6.8 100.0
3 98.9 9.9 7.3 99.2
4 90.5 28.2 8.3 97.6
5* 80.0 56.7 11.7 97.5
6 53.7 78.6 15.3 95.9
7 20.0 94.2 19.8 94.2
8 3.2 99.2 21.4 93.4
9+ 0.00 100.00 0.0 93.3
*Optimal cut-off for DM by Youden j index. PPV, Positive Predictive Value; NPV, Negative Predictive Value
https://doi.org/10.1371/journal.pone.0184840.t002
Validation of the ADA diabetes screening tools in Chinese
PLOS ONE | https://doi.org/10.1371/journal.pone.0184840 September 14, 2017 4 / 9
Discussion
In this study, we showed that the suggested recommendations by ADA were effective in
screening for undiagnosed cases of diabetes in our population. The ADA diabetes risk test has
a higher specificity, positive predictive value and positive likelihood ratio, but lower NNT com-
paring to the screening criteria with similar sensitivity, NPV and NDRL. The risk test appears
to be attractive as a non-invasive means to be used in the Chinese population as this approach
has high NPV, which is important as diabetes can be ruled out with high confidence, and the
NNT is low.
Both strategies include common conventional risk factors for diabetes but the number of
risk factors involved and their application are different. The risk test is based on the scores cal-
culated from seven health-related questions. The performance of its original model has been
robustly validated in different populations [8]. While the screening criteria are based mainly
on age and BMI as the perquisite factors for prediction, these two risk factors also have much
contribution to the scores of the risk test. Despite the mean BMI of our participants being only
24, about 60% of the participants were overweight or obese (Table 1) if we adopted the Asian
BMI cut-off for overweight at 23 kg/m2 [19, 20] as recommended by the ADA [6]. The scoring
of BMI for the on-line version of the risk test has also adopted the Asian criteria. Waist circum-
ference, despite also being used as a predictor in other screening tools [21, 22], was not
included in either screening methods recommended by ADA. This may have potential advan-
tage as the measurement of body weight and height is more precise than waist circumference,
which is heavily influenced by the anatomic location of measurement [23]. Age is well known
to be an important risk factor for diabetes. The screening criteria suggests that even without
the presence of other risk factors, regular testing of diabetes should start from the age of 45
and repeat every three years if the previous testing result is negative. If the ADA-suggested age
cut point at 45 years is used, for aging populations like the one in CRISPS4, a very high propor-
tion of the population would require regular testing for diabetes. On the other hand, the UK
National Screening Committee does not currently recommend universal screening for diabe-
tes based on age, but considers selective screening as part of an overall vascular risk assessment
using risk factors as the first stage of selection, followed by the measurement of blood glucose
[24]. Our findings would suggest that the ADA diabetes risk test may be considered as a better
alternative to the ADA screening criteria in our aging population as fewer people would
require regular testing for diabetes but the detection rate would be comparable.
Other health related questions asked in the risk test also include sex, history of gestational
diabetes in woman, physical inactivity, family history of diabetes and history of hypertension,
Table 3. Statistics measures of the performance of the two ADA screening strategies.
Diagnostic test
statistic
ADA diabetes risk test Cut-off5 ADA screening criteria Difference between two tests Ratio of two tests p-value
Sensitivity 0.80 (0.72–0.88) 0.81 (0.73–0.89) -0.01 (-0.11–0.09) 0.8348
Specificity 0.57 (0.54–0.59) 0.41 (0.38–0.43) 0.16 (0.13–0.19) <0.00001
PPV 0.12 (0.09–0.14) 0.09 (0.07–0.11) 1.31 (1.16–1.48) <0.00001
NPV 0.98 (0.96–0.99) 0.97 (0.95–0.98) 1.01 (0.99–1.02) 0.3050
PDLR 1.85 (1.64–2.08) 1.37 (1.23–1.52) 1.35 (1.18–1.55) <0.00001
NDLR 0.35 (0.24–0.53) 0.47 (0.31–0.71) 0.76 (0.45–1.27) 0.2895
NNT 11 (8.3–15.2) 18 (12.3–30.16)
PPV, Positive Predictive Value; NPV, Negative Predictive Value; PDLR, Positive Diagnostic Likelihood Ratio; NDLR, Negative Diagnostic Likelihood Ratio;
NNT, number needed to test for blood glucose levels to diagnose one case of diabetes
https://doi.org/10.1371/journal.pone.0184840.t003
Validation of the ADA diabetes screening tools in Chinese
PLOS ONE | https://doi.org/10.1371/journal.pone.0184840 September 14, 2017 5 / 9
which are conventional risk factors for diabetes without involvement of measurements or
invasive tests. The former three risk factors, however, did not show statistically significant dif-
ference in the diabetes subjects when compared with those without diabetes in our population
(Table 1). Each of these three risk factors, however, accounted only for one score point, which
was significantly less than the score points related to age and BMI. This might explain why the
risk test still performed well despite the inclusion of risk factors which were not statistically dif-
ferent between the diabetes and non-diabetes groups.
The definition of diabetes used in development of the ADA diabetes risk test was based on
fasting plasma glucose value. In this CRISPS cohort, subjects were also considered to have dia-
betes if they fulfilled either the fasting glucose or 2-hG criteria. We did not use HbA1c as a
diagnostic criterion for diabetes because the diagnostic criteria have changed over time with
HbA1c being adopted from 2011 onwards [25]. The HbA1c criterion would have diagnosed
an additional number of subjects with diabetes on top of the glucose criteria at CRISPS3 which
might affect the number of people without diabetes at CRISPS4, i.e. the study time frame of
this study [26]. Although currently HbA1c measurement may not be available throughout the
world, it will be increasingly used clinically for confirming the diagnosis of diabetes, being a
conveniently assessable parameter. If we included the HbA1c criterion for diagnosis of diabe-
tes in our analysis, more diabetes cases (157, 11.1%) would be diagnosed in the cohort but,
nonetheless, a similar conclusion would be drawn regarding the relative performance of the
two screening tests.
The risk test also has the advantage of being simple and applicable in various community or
clinical settings. It can be quickly calculated even manually. The time required is minimal and
the use of calculator or computer is not essential. Apart from being user-friendly, the risk test
has the advantage of better accuracy than existing scores from various populations with an
AUROC of 0.79 from the original 6 risk factors model [8]. When applied in the CRISPS4 pop-
ulation, the risk test still maintained reasonably good accuracy with an AUROC of 0.725. This
paper is, to our knowledge, the first paper to evaluate this risk test in a homogenous urban Chi-
nese population. Our findings suggest that the well validated ADA diabetes test also has a good
validity in detecting Chinese adults with undiagnosed diabetes in our population and could be
considered as an option for screening of diabetes in Chinese.
In interpreting our findings, we took into account several limitations. First, at CRISPS4, the
average age of the studied subjects was 58, with 43.9% of the subjects aged 45 or above
(Table 1). This was not representative of the general population but would be representative of
an older population likely to be offered diabetes screening. Second, in a long-term study, there
are inevitable losses to follow-up, including deaths. Comparing the baseline characteristics at
CRISPS1, the missing subjects were older (49±14 vs. 43±11, P<0.001), more of them were
men (51.8% vs. 46.2%, P = 0.003), ever smokers (30.5% vs. 21.7%, P<0.001) and with hyper-
tension (24.6% vs. 13.0% P<0.001). Fewer of them had family history of diabetes (15.2% vs.
18.3%, P = 0.026) The cohort might become less representative of the general population as
the defaulted subjects were more likely to be the high risk cases. Our study however has the
strengths of being a long-term cohort study in a genetically homogenous Chinese population.
The findings should be of considerable value in diabetes screening in Mainland China with its
huge aging population.
Conclusions
In conclusion, we recommend using the ADA diabetes risk test for identification of individuals
with increased risk of diabetes in the Chinese population. The test involves only personal med-
ical information and simple non-invasive measurements which should be acceptable by
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healthcare providers as well as individuals with different education levels. It can also be easily
adopted as a public health policy for identifying people with undiagnosed diabetes for early
and appropriate treatment to prevent the long-term diabetic complications [27]. Whether this
diabetes risk test is more effective than the age-based strategy for diabetes screening is an
important public health question to be further investigated in other aging populations.
Supporting information
S1 File. Baseline characteristics and risk of diabetes as assessed by the screening criteria or
risk test of 1415 subjects at CRISPS4. Screening criteria, the age- and body mass index-based
screening criteria; risk test, the ADA diabetes risk test.
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